aimediq
Intelligent Medical Systems

ReOxy®

Innovative Breathing Therapy for Enhanced Cardiac Rehabilitation

ReOxy® is CE-marked, approved, and intended for the improvement of physical exercise capacity in coronary artery disease patients. For professional use by healthcare facilities.

ReOxy® Therapy

An innovative approach in cardiac rehabilitation that uses controlled short-term intermittent hypoxia to stimulate adaptive physiological responses, enhancing cardiac function and patient outcomes.

ReOxy® therapy protocol involves repeated cyclic exposures to moderately reduced oxygen fractions (via a face mask), alternating with periods of mild hyperoxia.

One procedure
6-8 cycles

Total duration time
30-40 min

Course
10-15 treatment sessions
(4-7 sessions per week)





The blood saturation (SpO_2) and heart rate (HR) are individually monitored during every treatment session.

Clinical Effects

- **Improved tolerance to physical load,**
- **Management of noncardiac comorbidities: AH, diabetes mellitus, obesity,**
- **Reduced damaging effect of acute ischaemia episodes,**
- **Improvement in cognitive function,**
- **Reduced fatigue, breathlessness.**

Scan to see our **clinical evidence**

Application

Ischaemic Heart Disease

- Rehabilitation after MI
- Secondary prevention (managing cardiovascular risk)
- Multimorbid patients

Rehabilitation after cardiac surgery

Surgery preparation
(hypoxic preconditioning)

Post-COVID Syndrome

A unique solution for patients with reduced physical abilities and elderly

SAFE

ReOxy® therapy ensures significant benefits without inducing heart stress or damage, no severe side effects observed.

PERSONALIZED

ReOxy® pre-treatment test assesses an individual's hypoxia responsiveness, allowing for the safe regulation of SpO_2 and PR levels within a precise range.

SMART

Integrated AI-based software minimises human error, ensuring consistent and precise outcomes (Self-Regulated Treatment — SRT®).

Join us in advancing cardiac care

For Researchers:
invitation to collaborate on clinical studies.

For Healthcare Facilities:
get detailed information about incorporating ReOxy® into therapeutic practice.

For Innovators:
call for partnerships in AI/Data projects.

Clinical collaboration & recent projects

We have partnered with leading clinics and academic institutions to conduct research and development for applications of our technology.

Prof. Dr. Dr. med. Wolfram Doehner
University Professor at Charité Universitätsmedizin Berlin, Germany Berlin Institute of Health-Center for Regenerative Therapies and Deutsches Herzzentrum der Charité, (Campus Virchow), Center of Stroke Research Berlin; Charité Universitätsmedizin Berlin, Germany.

Treatment effect of respiratory therapy with intermittent hypoxic-hyperoxic training (IHHT) on functional capacity in patients with post COVID19 conditions: a controlled treatment trial (completed).

Results: The IHHT group demonstrated in comparison to controls a significant improved primary endpoint (6MWT difference, IHHT group vs. controls: 91.7 vs. 32.5m, *P*<0.001), improved stair climbing (SCT -1.9 vs. -0.5 sec, *P*<0.001), improved QoL (EQ5-D analogue scale change 31.3 vs. 2.9, *P*<0.001), improved fatigue (FAS -8.9 vs. 3.6, *P*<0.001) and improved perceived health (MCRS -10.3 vs. -2.0, *P*<0.001, all IHHT group vs. controls). The IHHT group exhibited a significant increase in haemoglobin content and a significant decrease in CRP compared to baseline (*P*<0.001), whereas these changes were not observed in the control group.

European Heart Journal, Volume 44, Issue Supplement_2, November 2023, ehad655.2594, https://doi.org/10.1093/eurheartj/ehad655.2594

Dr. Dr. rer. nat. habil.; Ph.D Boris Schmitz
Department of Rehabilitation Sciences, Faculty of Health, University of Witten/Herdecke, Germany. Principal Investigator and Head of Laboratory Member of the Timely

Use of intermittent hypoxic-hyperoxic training (IHHT) for adjunctive therapy in patients with coronary heart disease (in progress).

In patients with status post MI including interventional reperfusion procedures (1-3 vessels CAD, stenosis of left main coronary artery including post-STEMI/N-STEMI, post-stent implantation, where the myocardial infarction should not have been more than 6 weeks ago) with objective performance impairment in spiroergometry (VO2max < 75% of normal).

Stay connected & learn more

info@aimediq.com
www.aimediq.com

aimediq
Intelligent Medical Systems

Presented by Ai Mediq S.A
19, rue de Bitbourg
L-1723, Luxembourg
+352 27 860 697

Manufactured by Bitmos GmbH
37, Himmelgeister Str.
D-40225, Düsseldorf
Germany
+49 211 60 10 10 30

ReOxy is distributed in DE, LU, IT, CH,AT, UK, FI, LT, LV, EE, PO, AE, IL, KZ, SG, HK, TW, CN, MY, VN, AU